The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis

@article{Martinez2005TheCC,
  title={The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis},
  author={Fernando J. Martinez and Sharon Safrin and Derek Weycker and Karen M. Starko and Williamson Z. Bradford and Talmadge E. King and Kevin R. Flaherty and David A. Schwartz and Paul W. Noble and Ganesh Raghu and Kevin K Brown},
  journal={Annals of Internal Medicine},
  year={2005},
  volume={142},
  pages={963-967}
}
Context The natural history of idiopathic pulmonary fibrosis (IPF) is unclear. Contribution A total of 168 participants with mild to moderate IPF assigned to placebo in a randomized trial were followed at 12-week intervals for about 76 weeks. For 32 of 36 patients who died, IPF was a related or main cause of death. Although physiologic variables such as FVC changed little, acute clinical deterioration preceded death in half of the patients who died of IPF. Implications Clinicians may need to… Expand
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review
TLDR
Although significant progress in assessing disease severity in IPF has been made, AEs remain unpredictable and are associated with a high risk of death. Expand
Acute exacerbation of idiopathic pulmonary fibrosis.
TLDR
AE of IPF is a complication that demands additional careful study to clarify its relationship to the clinical course of patients with IPF. Expand
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
TLDR
In AE-IPF, the exclusion of alternative causes of rapid deterioration, including heart failure and infection, is the main goal of investigation, and empirical high-dose corticosteroid steroid therapy is generally used in AE- IPF, without proven benefit. Expand
Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis
TLDR
The present issue of European Respiratory Review reports the proceedings of an International Scientific Advisory Board Meeting on “Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis”, which was held in London (UK), on November 16–18, 2007. Expand
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
TLDR
The patient described in the present case study was a 65-yr-old male who presented with exertional dyspnoea and fever of 2 weeks' duration and it is presumed that in this case acute exacerbation developed in the very early course of IPF. Expand
Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review.
TLDR
A systematic review shows that the outcome of acute exacerbation of idiopathic pulmonary fibrosis is poor, with 1-month and 3-month mortality around 60% and 67%, respectively, and the potential role of newer agents in the management and prevention needs to be further clarified. Expand
Clinical course and prognosis in survivors of acute exacerbations of idiopathic pulmonary fibrosis.
TLDR
Among the survivors of first AE-IPFs, AE recurrence and pneumonia were the most common causes of death after discharge, therefore, preventing AE Recurrence and lung infections is crucial for prolonging survival in survivors of AE- IPFs. Expand
Acute exacerbations in idiopathic pulmonary fibrosis.
TLDR
An international effort to summarize the current state of knowledge regarding acute exacerbations of IPF is presented, and proposed diagnostic criteria include subjective worsening over 30 days or less, new bilateral radiographic opacities, and the absence of infection or another identifiable etiology. Expand
Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm
TLDR
A novel approach to the classification of acute respiratory worsening events in patients with IPF is proposed that focuses on clinical and radiological findings consistent with an underlying pathobiology of diffuse alveolar damage. Expand
Acute exacerbations in patients with idiopathic pulmonary fibrosis
  • D. Kim
  • Medicine
  • Respiratory Research
  • 2013
TLDR
There is emerging evidence from clinical trials of investigational therapies that chronic treatment of IPF may reduce the incidence of AEx-IPF, and the presence of comorbidities such as gastroesophageal reflux disease (GERD) and pulmonary hypertension may also increase the risk of an AEx -IPF. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment.
TLDR
In evaluating clinical deterioration in patients with IPF, disease-associated complications and adverse effects of therapy should be distinguished from progressive pulmonary fibrosis. Expand
Determinants of progression in idiopathic pulmonary fibrosis.
TLDR
Findings indicate that several clinical characteristics are independently associated with subsequent declines in TLC and DLCO in patients with IPF. Expand
CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis.
TLDR
CT patterns seen during periods of rapid deterioration in patients with IPF may allow predictions of prognosis and of response to treatment, and corresponded pathologically to acute diffuse alveolar damage. Expand
Acute exacerbation of idiopathic pulmonary fibrosis: report of a series
TLDR
Histological findings showed all the aspects of usual interstitial pnemonia with superimposed features of acute lung injury, such as diffuse alveolar damage, with or without hyaline membranes, type II reactive cells hyperplasia and numerous fibroblastic foci. Expand
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.
TLDR
In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Expand
Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases.
TLDR
Whether these two forms of interstitial pneumonia (UIP and acute lung injury pattern) are variants of one disease or are unrelated and also the effectiveness of corticosteroid therapy on such conditions remain to be determined by further studies. Expand
Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement
Many acute and chronic lung disorders with variable degrees of pulmonary inflammation and fibrosis are collectively referred to as interstitial lung diseases (ILDs) or diffuse parenchymal lungExpand
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.
TLDR
This work states that Idiopathic Pulmonary Fibrosis is a Specific Disease or a Histologic Manifestation of Many Diseases and AIP and UIP are Significance of NSIP. Expand
Serial computed tomographic evaluation in desquamative interstitial pneumonia.
TLDR
Some of the microcysts in DIP are different from the honeycomb cysts seen in UIP, and some of the cysts see in patients with DIP resolve with time, suggesting DIP does not progress to UIP in the short term. Expand
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors
TLDR
The Diagnostic Process Is Dynamic Clinical Evaluation Radiological Evaluation Role of Surgical Lung Biopsy Unclassifiable Interstitial Pneumonia Bronchoalveolar Lavage Fluid Evaluation Idiopathic Pulmonary Fibrosis. Expand
...
1
2
...